StockNews.AISignal intelligence
AMN Healthcare Services, Inc. · NYSE · Healthcare
Browse public AMN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
AMN's stock dropped 30% after Q3 report despite beating sales estimates. Q3 sales were $687.5 million, reflecting a 19% year-on-year decline. Adjusted EBITDA margin fell 500 bps to 10.7%, indicating operational struggles. Full-year revenue is expected to drop to $3.1 billion, a significant decline. Market conditions and cyclical declines may pressure AMN's future performance.
View signal analysisSmall-cap stocks surged, with Russell 2000 up 10.7% recently. Analysts caution against over-reliance on small-cap gains' fundamentals. AMN Healthcare expected to see earnings growth between 19% and 34% through 2026. Stocks meeting growth criteria may outperform in the near future.
View signal analysisSummary: - AMN Healthcare's Q1 2024 EPS declined 61% year over year. - Revenues for Q1 2024 were $820.9 million, beating estimates by 0.7%. - Nurse and Allied Solutions segment revenue down 37%, Technology and Workforce Solutions down 17.1%. - Margins contracted, operating profit declined, cash and debt positions changed. - Q2 2024 revenue outlook shows decline, with concerns about weaker demand. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis- AMN Healthcare reported earnings of $0.97 per share, beating estimates, with revenue of $820.88 million. - The company has surpassed consensus estimates four times in the last four quarters. - AMN Healthcare's stock has decreased by 19.5% this year, underperforming the S&P 500. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis